Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Transplant Proc ; 42(10): 4101-8, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21168637

RESUMO

BACKGROUND: Bleeding esophageal varices (BEV) in cirrhosis has been considered an indication for liver transplantation (LT). This issue was examined in a randomized controlled trial (RCT) of unselected, consecutive patients with advanced cirrhosis and BEV that compared endoscopic sclerotherapy (EST; n = 106) to emergency direct portacaval shunt (EPCS; n = 105). METHODS: Diagnostic work-up and treatment were initiated within 8 hours. Patients were evaluated for LT on admission and repeatedly thereafter; 96% underwent over 10 years of regular follow-up. The analysis was supplemented by 1300 unrandomized cirrhotic patients who previously underwent portacaval shunt (PCS) with 100% follow-up. RESULTS: In the RCT long-term bleeding control was 100% following EPCS, only 20% following EST. Also, 3-, 5-, 10-, and 15-year survival rates were 75%, 73%, 46%, and 46%, respectively, following EPCS compared with 44%, 21%, 9%, and 9% following EST, respectively (P < .001). Only 13 RCT patients (6%) were ultimately referred for LT mainly because of progressive liver failure; only 7 (3%) were approved for LT and only 4 (2%) underwent LT. The 1- and 5-year LT survival rates were 0.68% and 0, respectively, compared with 81% and 73%, respectively, after EPCS. In the 1300 unrandomized PCS patients, 50 (3.8%) were referred and 19 (1.5%) underwent LT. The 5-year survival rate was 53% compared with 72% for all 1300 patients. CONCLUSIONS: If bleeding is permanently controlled, as occurred invariably following EPCS, cirrhotic patients with BEV seldom require LT. PCS is effective first-line and long-term treatment. Should LT be required in patients with PCS, although technically more demanding, numerous studies have shown that PCS does not increase mortality or complications. EST is not effective emergency or long-term therapy.


Assuntos
Tratamento de Emergência , Varizes Esofágicas e Gástricas/cirurgia , Cirrose Hepática/cirurgia , Transplante de Fígado , Doença Aguda , Humanos , Taxa de Sobrevida , Resultado do Tratamento
2.
Hepatology ; 21(4): 1011-7, 1995 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-7705773

RESUMO

Portal hypertensive gastropathy is a vascular disorder of the gastric mucosa distinguished by ectasia of the mucosal capillaries and submucosal veins without inflammation. During 1988 to 1993, 12 patients with biopsy-proven cirrhosis (10 alcoholic, 2 posthepatitic) were evaluated and treated prospectively by portacaval shunt for active bleeding from severe portal hypertensive gastropathy. Eleven patients had been hospitalized for bleeding three to nine times previously, and one was bleeding uncontrollably for the first time. Requirement for blood transfusions ranged from 11 to 39 units cumulatively, of which 8 to 30 units were required specifically to replace blood lost from portal hypertensive gastropathy. Admission findings were ascites in 9 patients, jaundice in 8, severe muscle wasting in 10, hyperdynamic state in 9. Child's risk class was C in 7, B in 4, A in 1. Ten of the 12 patients had previously received repetitive endoscopic sclerotherapy for esophageal varices, which has been reported to precipitate portal hypertensive gastropathy. Eight patients had failed propranolol therapy for bleeding. Portacaval shunt was performed emergently in 11 patients and electively in 1, and permanently stopped bleeding in all by reducing the mean portal vein-inferior vena cava pressure gradient from 251 to 16 mm saline. There were no operative deaths, and two unrelated late deaths after 13 and 24 months. During 1 to 6.75 years of follow-up, all shunts remained patent by ultrasonography, the gastric mucosa reverted to normal on serial endoscopy, and there was no gastrointestinal bleeding. Recurrent portal-systemic encephalopathy developed in only 8% of patients. Quality of life was generally good.(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Hemorragia Gastrointestinal/cirurgia , Hipertensão Portal/complicações , Derivação Portocava Cirúrgica , Antagonistas Adrenérgicos beta/uso terapêutico , Adulto , Feminino , Hemorragia Gastrointestinal/mortalidade , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Qualidade de Vida
3.
Ann Emerg Med ; 19(8): 861-4, 1990 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-2372167

RESUMO

IV verapamil is the preferred drug for the acute management of supraventricular tachyarrhythmias (SVTs) in the absence of contraindications to its use. SVT complicated by hypotension has been considered a relative contraindication for the use of IV verapamil. However, the efficacy of IV verapamil in the management of "rate-related" hypotension has not been specifically addressed. The purpose of this study was to assess the effects of IV verapamil in patients with SVTs and arterial hypotension. A retrospective and prospective study design was used. Inclusion criteria were SVT (QRS duration, less than 120 ms; R-R interval, regular or irregular), QRS rate of 140 or more, systolic blood pressure of 90 mm Hg or less, and normal mental status. We identified 21 episodes of SVT meeting inclusion criteria in 19 patients. SVT was due to atrioventricular node re-entry in 17, atrial fibrillation in three, and atrial flutter in one. There were seven men and 12 women, with a mean age (+/- SD) of 52 +/- 17 years. Systolic blood pressure before verapamil was 70 +/- 28 mm Hg, and QRS rate was 192 +/- 19. IV calcium was not administered before IV verapamil. After IV verapamil administration (mean dose, 6.5 +/- 4.3 mg), a positive response (conversion to sinus rhythm or ventricular rate of less than 120) was noted in 17 of 21 episodes (80%). Post-treatment systolic blood pressure increased to 98 +/- 16 mm Hg (P less than .005 vs pretreatment), and ventricular response rate decreased to 112 +/- 39 (P less than .001 by two-tailed paired t test).(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Pressão Sanguínea/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Hipotensão/complicações , Taquicardia Supraventricular/complicações , Verapamil/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Hipotensão/tratamento farmacológico , Injeções Intravenosas , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Estudos Retrospectivos , Taquicardia Supraventricular/tratamento farmacológico , Verapamil/administração & dosagem
4.
Crit Care Med ; 15(6): 554-8, 1987 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-3568724

RESUMO

Defibrillation after prolonged ventricular fibrillation (VF) is frequently followed by asystole or electromechanical dissociation (EMD) which are usually fatal. We studied the effects of glucagon, a known inotropic and chronotropic agent, during 19 episodes of postcountershock asystole/EMD in nine dogs. Systolic and diastolic aortic (Ao), left ventricular, pulmonary arterial, and right atrial (RA) pressures were recorded as was the instantaneous Ao-RA difference (coronary perfusion pressure) and coronary sinus blood flow (CSF) during closed-chest CPR. VF was induced electrically; 2 min later, a 400-J transthoracic shock was given. Countershock was always followed by asystole (n = 12) or EMD (n = 7). Conventional closed-chest CPR with a mechanical device was begun 30 to 60 sec after countershock and continued for 2 to 3 min. If a perfusing rhythm did not occur, glucagon (1 mg) was given iv and CPR continued for 2 to 3 min more. Glucagon had no significant effect on intravascular pressures, the coronary perfusion gradient, or CSF when compared to CPR alone. However, in 14 or 19 postcountershock episodes unresponsive to CPR alone, glucagon restored effective spontaneous circulation, i.e., successful cardiac resuscitation, due to its effects on the intrinsic pacemaker discharge rate. Glucagon has been previously shown to stimulate myocardial adenyl cyclase via nonadrenergic mechanisms. We conclude that when postcountershock asystole/EMD occurs, glucagon has a direct and favorable effect on cardiac resuscitation outcome due to its effects on pacemaker discharge rate which is not mediated by changes in myocardial blood flow or coronary perfusion pressure.


Assuntos
Glucagon/farmacologia , Hemodinâmica/efeitos dos fármacos , Ressuscitação , Fibrilação Ventricular/terapia , Animais , Cães , Cardioversão Elétrica , Eletrofisiologia , Feminino , Masculino
5.
Ann Emerg Med ; 15(2): 112-20, 1986 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-3511782

RESUMO

Clinically, countershock of ventricular fibrillation (VF) may result in asystole or a pulseless rhythm in more than 50% of attempts. We conducted a study to assess the effects of immediate artificial pacing, CPR, and adrenergic drug therapy in the management of postcountershock pulseless rhythms. Thirty-four episodes of VF followed by countershock were studied in eight anesthetized dogs. Transducer-tipped catheters were positioned in the ascending aorta (Ao) and right atrium (RA). A bipolar pacing catheter was advanced to the apex of the right ventricle and a catheter for measurement of coronary sinus blood flow (CSQ) (continuous thermodilution technique) was positioned in the coronary sinus. VF was induced electrically and a countershock at 400 J was given two minutes later; CPR was not performed during VF episodes. Countershock was followed by asystole or a pulseless rhythm in all animals. Immediate endocardial pacing (0.1 to 5 mA) of bradyarrhythmias produced electrical capture but did not result in arterial pressure pulses in any animal. After pacing, CPR was performed for two minutes or until restoration of spontaneous circulation (ROSC). During CPR, the diastolic coronary perfusion gradient (Ao-RA) was 20 +/- 7 mm Hg (mean +/- SD) and CSQ was 14 +/- 7 mL/min/100 g (53% +/- 43% of control). ROSC followed CPR of less than two minutes duration in 24% of VF study episodes. If ROSC did not follow two minutes of CPR, 1 mg epinephrine, or 50 micrograms or 100 micrograms isoproterenol was given IV.(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Arritmias Cardíacas/terapia , Estimulação Cardíaca Artificial , Cardioversão Elétrica/efeitos adversos , Epinefrina/uso terapêutico , Parada Cardíaca/terapia , Isoproterenol/uso terapêutico , Ressuscitação , Animais , Pressão Sanguínea/efeitos dos fármacos , Circulação Coronária/efeitos dos fármacos , Cães , Parada Cardíaca/etiologia , Parada Cardíaca/fisiopatologia , Frequência Cardíaca/efeitos dos fármacos , Fatores de Tempo , Fibrilação Ventricular/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA